The New Orleans-based company develops technologies to treat and extend the patency of dialysis access fistulae, grafts, and peripheral arteries. It aims to enable patients to lead healthier lives with fewer interventions while lowering costs.
Solaris develops its flagship SX vascular stent graft as a minimally invasive treatment for these conditions. It employs an advanced electrospinning PTFE impermeable membrane that prevents tissue ingrowth, maximizes patency, and reduces restenosis. The membrane encapsulates a nitinol stent that provides flexibility, high radial strength, and crush resistance for optimal blood flow.
According to the company, it already has enrollment underway for clinical trials of a first-of-its-kind drug-eluting vascular stent graft. Solaris said this would address the remaining unmet need in covered stens — edge stenosis.
“Solaris Endovascular represents a rare opportunity to start a new company that is revenue producing from the beginning, has a decade-plus manufacturing expertise in stents, stent grafts and endovascular drug delivery, and a proven product supported by clinical studies in multiple markets before entering the U.S.,” said Solaris CEO Randy Hubbell. “Our platform addresses a significant unmet need in both dialysis access and PAD, offering life-changing solutions for patients while setting a new standard in endovascular care.”
